New study tests best blood thinner combo for rare heart artery condition
NCT ID NCT07511257
First seen May 07, 2026 · Last updated Jun 17, 2026 · Updated 6 times
Summary
This study looks at 326 adults who had a heart attack and have a rare condition where their heart arteries are abnormally widened (coronary artery ectasia). It compares the standard treatment of two anti-clotting drugs (aspirin and clopidogrel) against one anti-clotting drug plus a blood thinner (rivaroxaban). The goal is to see which approach better prevents future heart problems without causing dangerous bleeding.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE CORONARY SYNDROMES (ACS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Instituto Nacional de Cardiologia "Ignacio Chávez"
RECRUITINGMexico City, Tlalpan, 14080, Mexico
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.